Fangzhou Inc. partnered with Innovent Biologics to merge digital health services with innovative therapies for metabolic diseases and weight management. The collaboration aims to revolutionize the weight management market in China, which is projected to reach US$14.9 billion by 2030. With a focus on diabetes and obesity, the partnership will leverage AI technology to enhance patient care and education. Innovent’s Mazdutide therapy has shown significant weight reduction benefits, positioning it as one of the top 10 most anticipated medicines globally in 2025. This collaboration will provide patients with convenient medication support and personalized guidance through AI-powered tools.

Read more at 1. “Tesla reports record profits in Q3, beating expectations” – CNBC

2. “Apple unveils new iPhone 13 with improved camera features” – Reuters

3. “Amazon announces plans to hire 55,000 new employees across the U.S.” – Wall Street Journal

4. “Facebook faces backlash over leaked documents revealing internal research on platform’s harmful effects” – CBS MarketWatch

5. “Microsoft acquires AI company Nuance Communications for $16 billion” – Barchart: Fangzhou and Innovent Biologics Form Strategic Alliance for